Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. - Wikidata - awgldk - TriplyDB

Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge.

Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge.

http://www.wikidata.org/entity/Q30362939

about

Use of Vaxfectin adjuvant with DNA vaccine encoding the measles virus hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques against measles virus Dissolving and biodegradable microneedle technologies for transdermal sustained delivery of drug and vaccine Influenza virus-like particles containing M2 induce broadly cross protective immunity Development of a vaccine against pandemic influenza viruses: current status and perspectives.Design of a heterosubtypic epitope-based peptide vaccine fused with hemokinin-1 against influenza viruses.Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments.Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses.Conservation and diversity of influenza A H1N1 HLA-restricted T cell epitope candidates for epitope-based vaccines.Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A(H1N1) 2009 virus in an age-dependent manner.Cross-protective immunity to influenza A viruses.Influenza vaccine immunology.Novel vaccines against influenza viruses.New technologies for influenza vaccines.Protective efficacy of a broadly cross-reactive swine influenza DNA vaccine encoding M2e, cytotoxic T lymphocyte epitope and consensus H3 hemagglutinin.Virus-like particles as universal influenza vaccines Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice Inhibition of influenza M2-induced cell death alleviates its negative contribution to vaccination efficiency.Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret Robust immunity and heterologous protection against influenza in mice elicited by a novel recombinant NP-M2e fusion protein expressed in E. coli In Vitro Evaluation of Influenza M2 and Leishmania major HSP70 (221-604) Chimer Protein DNA vaccines: ready for prime time?Mucosal vaccination with recombinant Lactobacillus casei-displayed CTA1-conjugated consensus matrix protein-2 (sM2) induces broad protection against divergent influenza subtypes in BALB/c mice.The signal peptide sequence impacts the immune response elicited by a DNA epitope vaccine.Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice.Technologies for enhanced efficacy of DNA vaccines.Self-Amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral Challenge The proteosomal degradation of fusion proteins cannot be predicted from the proteosome susceptibility of their individual components.Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus.Novel linear DNA vaccines induce protective immune responses against lethal infection with influenza virus type A/H5N1.Vaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infection Cross-protection against drifted influenza viruses: options offered by adjuvanted and intradermal vaccines Heterosubtypic protective immunity against widely divergent influenza subtypes induced by fusion protein 4sM2 in BALB/c mice.Vaxfectin: a versatile adjuvant for plasmid DNA- and protein-based vaccines.DNA vaccines: an historical perspective and view to the future.Cationic liposomal vaccine adjuvants in animal challenge models: overview and current clinical status.Vaxfectin adjuvant improves antibody responses of juvenile rhesus macaques to a DNA vaccine encoding the measles virus hemagglutinin and fusion proteins.Expression of H3N2 nucleoprotein in maize seeds and immunogenicity in mice.A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine.Monomeric M2e antigen in VesiVax® liposomes stimulates protection against type a strains of influenza comparable to liposomes with multimeric forms of M2e.Vaccines against epidemic and pandemic influenza

P2860

Q24658311-F4F4D96D-A17B-4889-9FC3-C64D2461A9B8 Q27013822-1049047D-0213-43C8-8A10-AE601AE8B438 Q28743472-FF20A6F6-D6C4-4B20-BD35-FF2919C4BF2F Q30373784-065926BE-1E7A-4170-9BDF-DF884D8564EE Q30373963-DD32938B-F2C6-4570-A9BF-3DD12C76D216 Q30375991-93A9A330-C100-4DEC-AFE9-ABE00BBB18CF Q30382097-F1B8C872-2F65-4F9B-941E-ED6B968B1B3D Q30384675-77AB3478-3D68-43DA-911C-E422B39465CB Q30395315-6187D6A7-895C-405E-8FB8-90B85665BDD1 Q30396399-F3BFA67F-E365-4BE6-BEC8-A196975A778D Q30398035-8B92DE01-4142-46F4-AD54-D74D1F76905B Q30407716-FE895FD0-1D50-4AB4-951A-EED584485F2C Q30411859-F6972767-F81E-4409-A1DF-57E85E01FB88 Q30418612-D4EB50E4-C17F-4D64-A290-7E6A032226A1 Q30421558-E9836FCB-60E7-4856-A097-31EBD6B61C39 Q30425194-DDA08064-6F5E-4DFD-B14A-FF0A71764411 Q33314897-9FDDF214-5379-42CD-B54F-48FBFF47B821 Q33547457-827B1BB5-46E8-4BF9-80C0-09F95EA779FE Q34533990-369E03D0-1C04-4AA5-9442-3A9BA28B8E7D Q34629573-E2867756-F9FC-4AD9-AD0A-B712BF277B2A Q34824179-37F20EDE-8372-42B5-B5A3-D47AA22DE4AC Q35142923-3A6297FA-DBF8-41B9-9A20-93E0039A5B99 Q35271066-5C70A744-A765-4C01-B721-ECB4C6B7B94A Q35656657-A72F0267-F614-4691-83BF-C44FFE34369E Q35802958-39705CE7-7ED5-48BB-AD66-70EB74F31665 Q36104042-D1CE555B-EB5F-4E34-8DB6-98D0D8D7E4D8 Q36662175-38FCB970-FF54-49DC-B95A-049E381B5B8D Q36694825-49F9D683-527D-493F-B06F-1132EAE08FBF Q37001633-3998D401-69BC-49A0-AA51-912B6E4FCE50 Q37127506-A59712A8-4D98-4DA7-88BF-B76769FD9A21 Q37478319-03395EE1-0EB5-48EF-B0EA-729AB4F8EA7C Q37582869-2886DAB5-8062-4830-ACE4-08DB4922EA52 Q37813689-DA559C2F-9D28-43DB-B4D6-4F54DDD01357 Q37825523-6B9F0CD7-4694-421F-9028-7C9F1AC35FFC Q38028994-CD799342-9465-45C8-9C16-228F8EB5AF19 Q42079721-E4D6A7FC-22E5-4EB4-A56F-2120B1F4F305 Q42166124-370ABAC3-B6AB-437B-BDA1-0A00D3A00A10 Q44341358-86A06CB7-FC47-4B20-99C7-F12293356C8B Q44504298-0A41CAFE-4C78-4ECF-AA39-610621A2706D Q56550815-B9B4B0BF-C2DC-4B70-8A4B-865C8B6E998C

P2860

Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge.

http://www.wikidata.org/entity/Q30362939

description

2007 nî lūn-bûn

@nan

2007 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի մարտին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Vaxfectin-formulated influenza ...... gainst lethal viral challenge.

@ast

Vaxfectin-formulated influenza ...... gainst lethal viral challenge.

@en

type

label

Vaxfectin-formulated influenza ...... gainst lethal viral challenge.

@ast

Vaxfectin-formulated influenza ...... gainst lethal viral challenge.

@en

prefLabel

Vaxfectin-formulated influenza ...... gainst lethal viral challenge.

@ast

Vaxfectin-formulated influenza ...... gainst lethal viral challenge.

@en

P1433

Q30362939-C647E4F6-AA8F-4959-9FAD-D29045527351

P1476

Q30362939-77921AFC-6091-482B-A3A9-7D36BB130BD0

P2093

Q30362939-22940037-C07C-464F-B205-15FF6A82CE00

Q30362939-25FEF7CB-754F-4098-8FB4-5A0831786B25

Q30362939-38E4F82C-5FD4-4D45-83B2-D2784A3DA0D4

Q30362939-3CD2EC62-FFB8-400C-9F2E-C84B6D1FFF9A

Q30362939-3FE1A1EB-1F13-4C1E-8663-A612FF5FB854

Q30362939-4A9D2469-07F8-41FF-9A16-035CB4B79BBF

Q30362939-5E03E84E-8FD5-4F60-AEBA-48F8016B95CC

Q30362939-713C2E69-A094-455A-B603-6059CF7FAB44

Q30362939-8329D4E1-E97F-42F1-90F7-99EA4AC17C58

Q30362939-8DA8512F-BBC5-4F24-95C6-772BE028128B

P304

Q30362939-CA1E90D7-5B38-4749-8AEC-F652DA9E5146

P31

Q30362939-FAEA00CD-004E-4BE4-A5B4-FCFF9C2321BD

P356

Q30362939-EC385FA4-F4EF-4864-BE15-5170FE2A2110

P433

Q30362939-17A073EC-96BB-405F-921E-D32AE8DA9E2C

P478

Q30362939-5E167593-2536-491D-9DCE-A574585D9D54

P577

Q30362939-D03EE95E-DBDE-4196-8366-299CFDA27308

P5875

Q30362939-718553AE-913B-4201-8507-50F00B48B1D2

P698

Q30362939-053309B3-8D41-4F7F-935F-AB2DE84DF58C

P356

P1433

P1476

Vaxfectin-formulated influenza ...... gainst lethal viral challenge.

@en

P2093

Alain Rolland

http://www.w3.org/2001/XMLSchema#string

Andrew Geall

http://www.w3.org/2001/XMLSchema#string

Catherine J Luke

http://www.w3.org/2001/XMLSchema#string

David C Kaslow

http://www.w3.org/2001/XMLSchema#string

Denis Rusalov

http://www.w3.org/2001/XMLSchema#string

Gretchen S Jimenez

http://www.w3.org/2001/XMLSchema#string

Joel Enas

http://www.w3.org/2001/XMLSchema#string

Larry R Smith

http://www.w3.org/2001/XMLSchema#string

Peggy Lalor

http://www.w3.org/2001/XMLSchema#string

Qun Wei

http://www.w3.org/2001/XMLSchema#string

P304

157-164

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/HV.3.5.4175

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2007-03-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6200149

http://www.w3.org/2001/XMLSchema#string

P698

17637571

http://www.w3.org/2001/XMLSchema#string